Bristol-Myers Squibb vs Oracle: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Oracle was founded in 1977 by Lawrence Joseph Ellison, Robert Nimrod Miner, Edward A. Oates and is led by Clay Magouyrk and Mike Sicilia.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Oracle
- Founded
- 1977
- Headquarters
- Austin, Texas, United States
- Current CEO
- Clay Magouyrk and Mike Sicilia
- Employees
- 141,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Oracle
Lawrence Joseph Ellison
Oracle possesses arguably the most aggressive, intensely competitive, and controversial founding story in the entire history of Silicon Valley, rooted entirely in a CIA contract and driven by arguably the most competitive billionaire in American business histo…
Robert Nimrod Miner
Bob Miner co-founded Oracle and served as the central technical architect behind the company's early database products. While Ellison drove sales and strategy, Miner focused on making the software work for demanding customers.
Edward A. Oates
Ed Oates co-founded Oracle in 1977 and played an important role in the company's early technical and product formation. He helped the young company take relational database concepts and present them in an usable, commercially credible way.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Oracle
- Larry Ellison1977–present
Co-founder, Chairman and Chief Technology Officer
As the legendary Founder and CTO, he maintains absolute, tyrannical control over the company's strategic direction, fiercely driving its massive pivot toward cloud computing and artificial intelligence.
Source - Safra Catz2014–2025
Executive Vice Chair (CEO 2014-2025)
Served as co-CEO from 2014 and sole CEO from 2019 until September 2025, when she became executive vice chair of the board.
Source - Hilary Maxson2021–present
Chief Financial Officer
She brings critical global financial expertise to the board's massive capital allocation strategies.
Source - Clay Magouyrk2025–present
Co-Chief Executive Officer
Previously president of Oracle Cloud Infrastructure, where he led the OCI build-out from its early engineering team. Named co-CEO on September 22, 2025 with responsibility tied to Oracle's AI infrastructure expansion.
Source - Mike Sicilia2025–present
Co-Chief Executive Officer
As Executive Vice President of Global Industries, he manages Oracle's massive push into highly specialized vertical software markets, particularly focusing on healthcare and telecommunications.
Source
Timeline: Bristol-Myers Squibb and Oracle side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1977Oracle
Oracle Founded
Larry Ellison, Bob Miner, and Ed Oates founded the company that became Oracle.
1986Oracle
Oracle IPO
Oracle went public on the Nasdaq in March 1986.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1994Oracle
Acquired Rdb
Oracle acquired Rdb in 1994.
2005Oracle
Acquired PeopleSoft
Oracle acquired PeopleSoft for $10.3 billion. Oracle acquired PeopleSoft to significantly expand its enterprise applications portfolio and compete more directly with SAP.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2008Oracle
Acquired BEA Systems
Oracle acquired BEA Systems for $8.5 billion. Oracle acquired BEA Systems to strengthen middleware, application server, and enterprise integration capabilities.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2010Oracle
Sun Microsystems Acquisition
Oracle acquired Sun Microsystems, adding Java, Solaris, and hardware assets.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2014Oracle
Ellison Steps Down as CEO
Larry Ellison stepped down as chief executive in September 2014, and Mark Hurd and Safra Catz became co-CEOs.
2016Oracle
Acquired NetSuite
Oracle acquired NetSuite for $9.3 billion. Oracle acquired NetSuite to strengthen its cloud-native ERP portfolio and reach mid-sized companies that were not ideal buyers for Oracle's traditional enterprise applications.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Oracle
Cerner Acquisition Completed
Oracle completed the Cerner acquisition and expanded into healthcare data systems.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Oracle
Clay Magouyrk and Mike Sicilia Named CEOs
Oracle promoted Clay Magouyrk and Mike Sicilia to Chief Executive Officers; Safra Catz became Executive Vice Chair.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Oracle
$67.357B FY2026 Revenue
Oracle reported record FY2026 total revenue of $67.357 billion.
2026Oracle
Q1 FY2027: $664B RPO
Oracle reported Q1 FY2027 revenue of $19.3B and RPO of $664B, and completed a $20B at-the-market common stock sale.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Oracle
- Cerner2022$28.3B
- NetSuite2016$9.3B
- Sun Microsystems2010$7.4B
- BEA Systems2008$8.5B
- Hyperion Solutions2007$3.3B
- Siebel Systems2006$5.8B
Questions about Bristol-Myers Squibb vs Oracle
Who is the CEO of Bristol-Myers Squibb Company and Oracle Corporation?
Bristol-Myers Squibb Company is led by Christopher Boerner and Oracle Corporation is led by Clay Magouyrk and Mike Sicilia. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Oracle Corporation?
Bristol-Myers Squibb Company was founded in 1887 — 90 years before Oracle Corporation, which was founded in 1977. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Oracle Corporation.
How many employees does Bristol-Myers Squibb Company have compared to Oracle Corporation?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Oracle Corporation employs approximately 141,000. Oracle Corporation has the larger workforce at 141,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Oracle Corporation headquartered?
Both Bristol-Myers Squibb Company and Oracle Corporation are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Oracle Corporation?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Oracle Corporation was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, Edward A. Oates.
Which company has a longer operating history — Bristol-Myers Squibb Company or Oracle Corporation?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Oracle Corporation has been in operation for around 49 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Oracle overview